HUMANIGEN

  • TickerHGEN.O
Olga Smolentseva
  • Olga Smolentseva

HUMANIGEN (NEUTRAL, TP USD17) | Clinigen agreement could provide early...

HUMANIGEN (NEUTRAL, TP USD17) | Clinigen agreement could provide early marketing opportunity for lenz

Olga Smolentseva
  • Olga Smolentseva

HUMANIGEN | NEUTRAL vs. BUY | USD17 VS. USD35 Anticipating more clarit...

HUMANIGEN | NEUTRAL vs. BUY | USD17 VS. USD35 Anticipating more clarity on the regulatory path forward for lenzilumab FDA declined the EUA application for lenzilumab in COVID-19 Potential regulatory path forward for lenzilumab in COVID-19 in the US Lenzilumab’s potential beyond COVID-19 Awaiting for more clarity in COVID-19, we lower TP to USD17 and downgrade to Neutral

Olga Smolentseva
  • Olga Smolentseva

HUMANIGEN (BUY, TP USD35) | Lenzilumab showed significant efficacy in ...

HUMANIGEN (BUY, TP USD35) | Lenzilumab showed significant efficacy in African-American population

Olga Smolentseva
  • Olga Smolentseva

HUMANIGEN (BUY, TP USD35) | MHRA accepts lenzilumab CMA submission of ...

HUMANIGEN (BUY, TP USD35) | MHRA accepts lenzilumab CMA submission of the expedited basis

Olga Smolentseva
  • Olga Smolentseva

HUMANIGEN (BUY, TP USD35) | More confidence in potential Lenz approval...

HUMANIGEN (BUY, TP USD35) | More confidence in potential Lenz approval following Mavri update:

Olga Smolentseva
  • Olga Smolentseva

HUMANIGEN (NEUTRAL, TP USD17) | Clinigen agreement could provide early...

HUMANIGEN (NEUTRAL, TP USD17) | Clinigen agreement could provide early marketing opportunity for lenz

Olga Smolentseva
  • Olga Smolentseva

HUMANIGEN | NEUTRAL vs. BUY | USD17 VS. USD35 Anticipating more clarit...

HUMANIGEN | NEUTRAL vs. BUY | USD17 VS. USD35 Anticipating more clarity on the regulatory path forward for lenzilumab FDA declined the EUA application for lenzilumab in COVID-19 Potential regulatory path forward for lenzilumab in COVID-19 in the US Lenzilumab’s potential beyond COVID-19 Awaiting for more clarity in COVID-19, we lower TP to USD17 and downgrade to Neutral

Olga Smolentseva
  • Olga Smolentseva

HUMANIGEN (BUY, TP USD35) | Lenzilumab showed significant efficacy in ...

HUMANIGEN (BUY, TP USD35) | Lenzilumab showed significant efficacy in African-American population

Olga Smolentseva
  • Olga Smolentseva

HUMANIGEN (BUY, TP USD35) | MHRA accepts lenzilumab CMA submission of ...

HUMANIGEN (BUY, TP USD35) | MHRA accepts lenzilumab CMA submission of the expedited basis

Olga Smolentseva
  • Olga Smolentseva

HUMANIGEN (BUY, TP USD35) | More confidence in potential Lenz approval...

HUMANIGEN (BUY, TP USD35) | More confidence in potential Lenz approval following Mavri update:

ResearchPool Subscriptions

Get the most out of your insights

Get in touch